Financings in Brief: Spectral Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Spectral Diagnostics: Announces that its North and South American marketing partner Dade International will exercise warrants to buy for $2 mil. 123,839 shares of common stock in Spectral. The warrants are related to an investment made in 1993 by Baxter, which has since sold its diagnostic manufacturing businesses (now operating under the name Dade) to Bain Capital. Spectral says that the purchase of the additional shares is "a result of the successful U.S. product introduction" of its Status CK-MB/Myoglobin panel test...